Table 1.
Mean Age, Mean Duration of Illness and Illness Severity Assessments by Intervention Group for Laboratory-Confirmed Symptomatic Influenza Type A (H3N2) and Type B
| Group, characteristic | LAIV arm | TIV arm | Placebo arm | Total |
| Subjects with laboratory-confirmed symptomatic influenza A (H3N2) | ||||
| No. of subjects | 80 | 42 | 44 | 166 |
| Age, mean years ± SDa | 24.8 ± 8.9 | 26.8 ± 9.6 | 22.8 ± 7.1 | 24.7 ± 8.7 |
| Duration of illness, mean days ± SD | 6.5 ± 4.5 | 6.1 ± 5.7 | 7.1 ± 6.4 | 6.6 ± 5.4 |
| Reported symptoms of fever/feverishness and cough | 72 (90.0) | 35 (83.3) | 37 (84.1) | 144 (86.7) |
| Reported severe symptoms | 54 (67.5) | 24 (57.1) | 30 (68.2) | 108 (65.1) |
| Health care provider contactb | 27 (34.6) | 8 (19.5)d | 19 (43.2) | 54 (33.1) |
| Subjects with laboratory-confirmed symptomatic influenza B | ||||
| No. of subjects | 9 | 9 | 11 | 29 |
| Age, mean years ± SDc | 25.3 ± 11.5 | 31.0 ± 9.4 | 26.9 ± 8.7 | 27.7 ± 9.8 |
| Duration of illness, mean days ± SD | 8.4 ± 3.9 | 3.7 ± 3.1 | 9.4 ± 7.2 | 7.3 ± 5.6 |
| Reported symptoms of fever/feverishness and cough | 7 (77.8) | 8 (88.9) | 7 (63.6) | 22 (75.9) |
| Reported severe symptoms | 5 (55.6) | 7 (77.8) | 5 (45.5) | 17 (58.6) |
| Health care provider contactb | 4 (44.4) | 1 (12.5) | 4 (36.4) | 9 (32.1) |
NOTE. Data are no. (%) of subjects, unless otherwise indicated. LAIV, live attenuated vaccine; SD, standard deviation; TIV: trivalent inactivated vaccine.
a
Subjects were aged 18–48 years.
b
Numbers do not add to expected totals due to missing data.
c
Subjects were aged 18-46 years.
d
For TIV vs placebo arms, - P < .05(by χ2 test).